Question 1

What is the catalog number for 4-Chloro-2,3-difluorobenzaldehyde?

Accepted Answer

The catalog number for 4-Chloro-2,3-difluorobenzaldehyde is 431564.

Question 2

What sizes are available for 4-Chloro-2,3-difluorobenzaldehyde?

Accepted Answer

4-Chloro-2,3-difluorobenzaldehyde is available in the following size(s): 250 mg, 2.5 g.

Question 3

How many pack sizes does 4-Chloro-2,3-difluorobenzaldehyde come in?

Accepted Answer

4-Chloro-2,3-difluorobenzaldehyde is available in 2 different pack sizes.

Question 4

Is 4-Chloro-2,3-difluorobenzaldehyde in stock?

Accepted Answer

4-Chloro-2,3-difluorobenzaldehyde is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What should I do if I need to report a performance issue with a specific lot of this product?

Accepted Answer

Provide the catalogue number, product name, lot number, and your experimental results to our technical support team. They’ll investigate and, if needed, escalate to the manufacturer, provided the product was used before expiry and stored correctly.

Question 6

What is the isotype of this antibody?

Accepted Answer

Isotype information such as IgG1 or IgG2a is listed in the product specifications on the datasheet, relevant for selecting compatible detection reagents.

Question 7

Can I get a trial-size or discounted first order of this product?

Accepted Answer

We don’t generally offer free samples, but trial discounts in exchange for feedback and validation results are almost always possible. Contact us with your intended application to arrange one.

4-Chloro-2,3-difluorobenzaldehyde

Product Specifications

Available Sizes

Frequently Asked Questions

Explore Other Products

ATP6V1C2 Mouse Monoclonal Antibody [Clone ID: OTI8C2]

Mouse Cyp7a1 activation kit by CRISPRa

Vmn1r181 Mouse Gene Knockout Kit (CRISPR)

7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin-d3

Occludin (OCLN) (Tight Junctions Marker) (OCLN/2183), CF405S conjugate, 0.1mg/mL

TIGD5 Human Gene Knockout Kit (CRISPR)